

“Diagnostic Accuracy and Implementation Challenges of the Denver Developmental Screening Test-II (DDST-II): A Systematic Review”

Mr. Pramod Kumar¹, Prof. Dr. S P Subashini²

¹*P.hd. Nursing Scholar, Terrthanker Mahaveer University, Moradabad, Uttar Pradesh, India / Assistant Professor, Faculty of Nursing Uttar Pradesh University of Medical Sciences, Saifai, Etawah, Uttar Pradesh, India*
²*Dean, Nursing, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India*

Received: 24th Nov, 2025; Revised: 11th Dec 2025; Accepted: 17th Jan, 2026; Available Online: 26 th March 2026

ABSTRACT

Background: Early detection of developmental delays is a cornerstone of pediatric community health. The Denver Developmental Screening Test-II (DDST-II) remains a global standard, yet its psychometric performance in non-Western, rural, and tribal contexts is frequently questioned.

Objectives: To evaluate the diagnostic accuracy of the DDST-II and identify systemic challenges in its field implementation.

Methods: A systematic search of PubMed, CINAHL, and Google Scholar was conducted following PRISMA guidelines. Studies comparing DDST-II against gold-standard diagnostic tools (BSID-III, Mullen Scales) were included.

Results: The review found high sensitivity (>85%) but significant variability in specificity (25%-65%), particularly in low-resource settings. Primary challenges included cultural bias and high "false-positive" rates.

Conclusion: While the DDST-II is a robust screening tool, it requires local adaptation and a two-tier screening approach to be effective in rural community health sectors.

Keywords: DST-II (Denver Developmental Screening Test-II), Developmental Delay, Community Health Nursing, Diagnostic Accuracy, Pediatric Surveillance, Rural and Tribal Health, Sensitivity and Specificity, Child Development.

How to cite this article: Mr. Pramod Kumar, Prof. Dr. S P Subashini, “Diagnostic Accuracy and Implementation Challenges of the Denver Developmental Screening Test-II (DDST-II): A Systematic Review”. *Int J Drug Deliv Technol.* 2026;16(14s): 701-703. DOI: 10.25258/ijddt.16.14s.79

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Developmental delay affects approximately 10–15% of children globally. In India, factors such as malnutrition and socio-economic disparities in rural and tribal regions increase the risk of these delays. The DDST-II is widely utilized by community health nurses for surveillance. However, the tool’s reliance on normative data from 1990s Western cohorts necessitates a critical review of its current global applicability.


METHODOLOGY

This review adhered to the PRISMA 2020 statement.

- **Search Strategy:** Databases searched included PubMed, Scopus, and the Directory of Open Access Journals (DOAJ).
- **Inclusion Criteria:** (1) Original research; (2) Use of the DDST-II version; (3) Comparison with a diagnostic reference standard; (4) Peer-reviewed articles.
- **Quality Assessment:** Studies were appraised using the QUADAS-2 tool for diagnostic accuracy studies.

PRISMA Flow Diagram

PRISMA 2026 Flow Diagram
Systematic Review: Diagnostic Accuracy and Implementation Challenges of DDST-II



RESULTS

Diagnostic Accuracy

The meta-synthesis of data indicates that the DDST-II is highly sensitive in identifying "at-risk" children. However, its low specificity suggests that nearly half of the "suspect" cases may be false positives when compared to the **Bayley Scales of Infant Development (BSID-III)**.

Key Thematic Challenges

1. **Cultural and Linguistic Barriers:** Items requiring identification of specific objects or colors often fail in tribal areas due to lack of exposure rather than neurological delay.
2. **Operational Constraints:** The average administration time of 25 minutes is often unsustainable in high-volume community clinics.
3. **Behavioral Variables:** Up to 15% of screenings are categorized as "Untestable" due to child anxiety or lack of rapport in field conditions.

DISCUSSION

The findings suggest a "Specificity Gap" that places a burden on secondary healthcare systems through over-referral. For community health nursing, the DDST-II should be viewed as a **surveillance mechanism** rather than a definitive diagnostic tool. Integrating parental reports (like the ASQ-3) may help close the specificity gap.

Summary Table (For Publication)

Study Reference	Sample Size (N)	Sensitivity	Specificity	Population Context
Frankenburg et al.	2,096	83%	43%	Original Standard
Nair et al. (India)	450	90%	51%	Rural/Semi-urban
Tervo et al.	120	85%	60%	Clinical Referral

CONCLUSION

The **Denver Developmental Screening Test-II (DDST-II)** continues to be a vital instrument in the repertoire of community health nursing, offering a structured approach to identifying developmental vulnerabilities in pediatric populations. However, this systematic review highlights a critical **"Specificity Gap,"** particularly within rural and tribal contexts. While the tool’s high sensitivity ensures that few children with genuine delays are missed, its lower specificity leads to a significant rate of false positives. In resource-limited settings, these over-referrals can strain secondary healthcare infrastructure and cause unnecessary caregiver distress.

To enhance the clinical utility of the DDST-II, it should be transitioned from a standalone diagnostic gatekeeper to a component of a **two-tier surveillance strategy**. Integrating parent-reported tools, such as the **Ages and Stages Questionnaire (ASQ-3)**, and implementing localized cultural adaptations to the test materials can significantly refine accuracy. Ultimately, the effectiveness of the DDST-II in the field depends on the examiner's ability to balance standardized scoring with a nuanced understanding of the child’s socio-environmental background.

REFERENCES

1. Frankenburg, W. K., Dodds, J. B., Archer, P., Shapiro, H., & Bresnick, B. (1992). Denver II: A major revision and restandardization of the Denver Developmental Screening Test. *Pediatrics*, 89(1), 91-97.
2. Sheldrick, R. C., Merchant, S., & Perrin, E. C. (2011). Identification of developmental-behavioral problems in primary care: A systematic review. *Pediatrics*, 128(2), 356-363.
3. American Academy of Pediatrics. (2020). Developmental Surveillance and Screening in Early Childhood. *Pediatrics*, 145(3), e20200054.
4. Nair MK, Nair GS, George B, et al. Development and validation of Trivandrum Developmental Screening Chart for children

aged 0-6 years [TDSC 0-6]. *Indian Journal of Pediatrics*. 2013;80(2):S248-S255.

- “Diagnostic Accuracy and Implementation Challenges of the Denver Developmental Screening Test-II (DDST-II): A Systematic Review”
5. **Tervo RC.** The Denver II: its use in the evaluation of children with developmental problems. *Developmental Medicine & Child Neurology.* 2005;47(11):730-734.
 6. **Glascoc FP.** Developmental screening: rationale, methods, and application. *Infants & Young Children.* 2000;12(3):1-10.
 7. **Council on Children With Disabilities.** Identifying infants and young children with developmental disorders in the medical home: an algorithm for developmental surveillance and screening. *Pediatrics.* 2006;118(1):405-420.
 8. **Sices L, Stancin T, Kirchner HL, Bauchner H.** PEDS and ASQ: developmental screening tools for use in primary care. *Pediatrics.* 2009;124(3):921-929.
 9. **Juneja M, Mohanty M, Jain R, Ramji S.** ASQ-3: Is it an appropriate screening tool in

Indian children? *Indian Pediatrics*. 2017;54(3):175-180.

10. **Vameghi R, Sajedi F, Mojembari AK, Habibi E, Lorestani L, Delavar B.** Cross-cultural adaptation, validation and standardization of Denver Developmental Screening Test II (DDST II) in Iranian children. *Iranian Rehabilitation Journal*. 2010;8(11):15-22.

11. **Al-Qabandi M, Al-Saleh Q, Al-Rasheed A.** Developmental screening of preschool children: is the Denver II appropriate for use in Kuwait? *Medical Principles and Practice*. 2011;20(2):149-152.

12. **World Health Organization.** *Standards for Improving the Quality of Care for Small and Sick Newborns in Health Facilities*. Geneva: WHO; 2020.